Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (VRTX)
NASDAQ:VRTX
VRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$377.85 - $519.88
Previous CloseN/A
Volume295.43K
Average Volume (3M)1.64M
Market Cap
$122.24B
Enterprise Value$100.53B
Total Cash (Recent Filing)$396.55M
Total Debt (Recent Filing)$125.32M
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 05, 2025EPS Estimate
4.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.20
Shares Outstanding257,080,840
10 Day Avg. Volume2,122,713
30 Day Avg. Volume1,640,310
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.73
Price to Cash Flow (P/CF)55.30
P/FCF Ratio54.90
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.59
Enterprise Value/Ebitda206.73
Forecast
1Y Price Target
$499.23Price Target Upside3.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering27
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceJournavx's contribution to the revised price objective has increased, reflecting its potential impact on financial performance.
Pipeline DevelopmentProgress for zimislecel continues with a pivotal trial underway, potentially leading to regulatory submission in 2026.
Product LaunchScripts available from the first four weeks of Journavx's launch continue to track well, showing strong initial demand.
Bears Say
Clinical TrialsVertex announced plans to discontinue its VX-264 program in T1D due to lack of efficacy, impacting investor sentiment negatively.
Product LimitationsThe required use of immunosuppressants with zimislecel could limit its uptake compared to expectations for VX-264.
Regulatory ChallengesThe majority of practices have yet to implement an official formulary coverage policy, which could take an average of 21 weeks to finalize.
---
Ownership Overview
0.21% Insiders
36.84% Mutual Funds
30.60% Other Institutional Investors
7.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VRTX FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was $377.85 and its highest was $519.88 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Vertex Pharmaceuticals’s market cap is $122.24B.
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is May 05, 2025 which is in 22 days.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on Feb 10, 2025. The company reported $3.98 earnings per share for the quarter, missing the consensus estimate of $4.016 by -$0.036.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Undervalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is 4.27.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 257,080,840 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of $3.98 in its last earnings report, missing expectations of $4.016. Following the earnings report the stock price went down -3.138%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Currently, no hedge funds are holding shares in VRTX
---
Vertex Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$499.23 (3.10% Upside)
$499.23 (3.10% Upside)
Blogger Sentiment
Bullish
VRTX Sentiment 96%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 230.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days >0.1%
Last 30 Days >0.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
20.98%
12-Months-Change
Fundamentals
Return on Equity
-3.15%
Trailing 12-Months
Asset Growth
0.02%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
---
VRTX Company Deck
---
VRTX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and successful product launches, signaling a positive momentum for Vertex's commercial and R&D efforts. However, the call also acknowledged challenges such as IP violations in Russia and increased operating expenses affecting profitability.Read More>---
VRTX Revenue Breakdown
60.66% U.S.
39.34% Europe
---
VRTX Stock 12 Month Forecast
Average Price Target
$499.23
▲(3.10% Upside)
Technical Analysis
Best Analysts Covering VRTX
1 Year
1 Year Success Rate
14/16 ratings generated profit
1 Year Average Return
+21.66%
reiterated a buy rating 2 months ago
Copying Olivia Brayer's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +21.66% per trade.
---